Microcap Ledger Actuate Therapeutics, Inc. $ACTU
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Fort Worth, TX
- Fiscal year end
- December 31
- Shares outstanding
- 24,014,202 [10-Q 2026-08-14]
What the company doesAI summary of filing
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing elraglusib, a small-molecule GSK-3β inhibitor for treating difficult-to-treat cancers. The company is advancing two formulations: elraglusib injection, which showed statistically significant survival benefits in a Phase 2 trial for metastatic pancreatic ductal adenocarcinoma when combined with standard chemotherapy, and an oral tablet formulation in early development. Elraglusib has been tested in over 500 patients across multiple cancer types including pancreatic cancer, pediatric cancers, melanoma, and colorectal cancer. The company generates no revenue and is pursuing clinical development programs pending adequate funding and potential strategic partnerships. [10-K 2026-03-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$10.49M | −$9.42M | $4.43M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$22.23M | −$19.21M | $13.16M | [10-K 2026-03-26] |
| FY ended Dec 2024 | — | −$27.29M | −$21.84M | $8.64M | [10-K 2026-03-26] |
- Quarterly cash burn
- −$4.71M
- Cash runway Estimate
- ~2.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-11 | 19,531,636 | [10-Q 2024-11-13] |
| 2025-03-10 | 19,531,636 | [10-K 2025-03-13] |
| 2025-05-14 | 19,619,660 | [10-Q 2025-05-15] |
| 2025-08-13 | 20,745,187 | [10-Q 2025-08-14] |
| 2025-11-12 | 23,243,328 | [10-Q 2025-11-13] |
| 2026-03-25 | 23,709,943 | [10-K 2026-03-26] |
| 2026-05-13 | 23,925,852 | [10-Q 2026-05-14] |
| 2026-08-13 | 24,014,202 | [10-Q 2026-08-14] |
- Shelf registration
- S-1 filed 2026-10-06; no effectiveness notice found in EDGAR [S-1 2026-10-06]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-17. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-07-17 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-17] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-14 | Schmitt Daniel M | exercise | 272,056 | — | [4 2026-08-14] |
| 2026-08-14 | Schmitt Daniel M | other | 120,521 | $1.01 | [4 2026-08-14] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-06 | S-1 | Registration statement |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-07-17 | 8-K | Listing notice or transfer |
| 2026-05-22 | 8-K | Shareholder vote results |
| 2026-05-14 | 10-Q | Quarterly report |
| 2026-05-11 | 8-K | Regulation FD disclosure |
| 2026-05-06 | 8-K | Director or officer change; Other events |
| 2026-04-22 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-04-06 | DEF 14A | Proxy statement |
| 2026-03-26 | 10-K | Annual report |
| 2026-01-12 | 8-K | Regulation FD disclosure |
| 2025-12-17 | 13G | Beneficial ownership report (5%+ holder) |
Alerts for $ACTU
Email me when Actuate Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.